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A synthetic progestin, medroxyprogesterone acetate (MPA), was used in a novel study to
determine progestin effects on human purified macrophages and Th1, Th2, Th17, Th22
cells. MPA concentrations were equivalent to those in the serum of women after 6 and
9 months of progestin use. MPA has no effect on the proliferation of PBMCs and CD4+
T cell clones induced by immobilized anti-CD3 antibodies or by antigen (streptokinase).
However, MPA decreases production and mRNA expression of IL-5, IL-13, IFN-γ, T-bet,
RORC, and IL-17A but increases production and mRNA expression of IL-22 by CD4+
Th22 cell clones and decreases IL-22 production by Th17 cells. MPA inhibits RORC,
but not T-bet and AHR, by Th17 cells but increases AHR mRNA and T-bet expression of
established CD4+ Th22 cell clones. This suggests that MPA, at concentrations equivalent
to those found in the serum of women after treatment for contraception and hormone
replacement therapy, can directly inhibit Th1 responses (against intracellular bacteria and
viruses), Th17 (against extracellular bacteria and fungi), Th2 (against parasites) but MPA
therapy increases IL-22 produced by Th22 cells mediated by an increased expression of
AHR and T-bet controlling inflammation. MPA could be responsible for the tissue damage
limited by IL-22 in absence of IL-17A.
Keywords: hormone replacement therapy, contraception, medroxyprogesterone acetate, Th1, Th2, Th17, Th22,
infection
INTRODUCTION
Different CD4+ T helper (Th) lymphocytes have been classified into different functional subsets
based on their profile of cytokine production. Type 1 Th (Th1) cells produce interferon-gamma
(IFN)-γ, interleukin (IL)-2, and tumor necrosis factor (TNF)-β. They also promote the production
of opsonizing and complement-fixing antibodies, macrophage activation, antibody-dependent cell
cytotoxicity and delayed type hypersensitivity (1, 2). Type 2 Th (Th2) cells produce IL-4, IL-5, and
IL-13 and provide optimal help for humoral immune responses, including IgE isotype switching
and mucosal immunity, through mast cell and eosinophil differentiation and facilitation of IgA
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synthesis. In addition, some Th2-derived cytokines, such as IL-
4 and IL-10, inhibit several macrophage functions (1, 2). An
additional subset of CD4+T helper cells beyond the traditional
Th1 and Th2 cells has been identifiedmore recently, i.e., the Th17
cell, which produces IL-17A, IL-17F, IL-21, IL-26, and IL-22 (3).
The major role of Th17 is the protection against extracellular
bacteria and fungi. These cells are also pathogenic in several
murine models of chronic inflammatory disorders.
Th22 cells primarily secrete IL-22, IL-13, and TNF-alpha.
Similar to Th17 cells, Th22 cells express CCR4, and CCR6,
but they do not express IL-17, CCL20, IL-23R, CD161 (Th17
markers), IL-4 (Th2 marker), or IFN-gamma (Th1 marker).
The expansion of IL-22-producing cells appears to be regulated
by the aryl hydrocarbon receptor (AHR) transcription factor,
although additional intracellular molecules involved in Th22
differentiation are still being investigated. Expression of the
CCR4 and CCR10 skin-homing receptors on Th22 cells
suggests these cells are likely recruited to the skin where they
may contribute to host defense against microbial pathogens,
and promote tissue repair or remodeling. Th22 cells may
also be involved in the pathogenesis of inflammatory skin
disorders such as psoriasis, atopic eczema, and allergic contact
dermatitis (4, 5).
The development of Th1- or Th2-dominated responses
depends on several factors, the most critical being cytokines
produced in the microenvironment during antigen presentation.
The differentiation of Th cells into polarized Th1 or Th2 cells
can also be influenced by certain hormones. Some years ago, we
showed that progesterone is a potent inducer of helper 2 (Th2)
type cytokines (IL-4 and IL-5), leukemia inhibitory factor (LIF)
and macrophage colony-stimulating factor (M-CSF) (6, 7). The
ability of progesterone to suppress cell-mediated functions via
the production of Th2-type cytokines has suggested that the high
levels of progesterone in human placenta are of great relevance
for the maintenance of pregnancy by promoting the tolerance
of the fetus assimilated to an allograft (6–16). Recently, it has
been shown that progesterone induces the expression of TSLP
(an inducer of Th2-type responses) and inhibits the expression
of Th17 related transcription factor RORγt, reducing the influx
of neutrophils in murine vaginal gonococcal infection (17).
Synthetic progestins are selected for clinical use primarily
to mimic the actions of endogenous progesterone, produced
predominantly by the ovaries. The relatively short half-life of the
reproductive steroids has, until recently, obviated the therapeutic
goal of providing physiological hormone replacement unless
parent compounds are pharmaceutically modified to prolong
their action. MPA was developed to provide a safe, effective
synthetic progestin to women requiring hormone therapy (HRT)
and/or contraception. It has selective activity quite similar
to progesterone itself (18). As expected, MPA has a more
favorable bioavailability and a longer half-life than progesterone.
Consequently, we were interested in the possibility that the
synthetic progestin, MPA, which mimics progesterone effects
could also influence T cell cytokine production.
Medroxyprogesterone acetate (MPA), a 17α-
hydroxyprogesterone derivative, is a synthetic analog of the
natural steroid progesterone. Since its development more
three decades ago, MPA has been employed in the treatment
of mammary and endometrial adenocarcinomas (19), as a
supportive therapy in the anorexia/cachexia syndrome (20) and
is also the most widely used injectable female contraceptive.
Known as Depo-Provera, MPA is provided as a long-acting
contraceptive (21), with at least 20 million current users
worldwide (22). MPA is also the most commonly used progestin
in the USA and Europe for hormone replacement therapy
(23). The doses of MPA used in humans vary. A single 150mg
intramuscular injection every 3 months (24) creates circulating
Cmax MPA levels ranging from 0.32 to 3.7 ng/ml and Cmin
MPA levels of 0.04 to 1.31 ng/ml (25). After a single injection
of 150 mg MPA, time to Cmax is ∼9 days (Package insert,
Depo-Subq Provera). Earlier estimates of MPA levels following a
single sc injection of this MPA dose are consistent with current
measurements: serum concentrations of MPA showed a brief
initial elevation ranging from 1.5 to 3 ng/ml for a few days with
a gradual decline to about 1 ng/ml for 2–3 months, decreasing
gradually to 0.2 ng/ml during the sixth month to <0.02 ng/ml at
about 7.5 to 9 months following administration (26). The blood
level of MPA that suppresses ovulation is ∼0.1 ng/ml (26). Oral
MPA has also been used in contraceptive preparations and most
commonly for HRT (10mg to 1.25mg daily). The Cmax for two
PREMPRO tablets containing 1.5mg MPA/tablet is 1.2 ng/ml
which is achieved within 2.8 h (Package insert, PREMPRO).
Additionally, very high doses of MPA (2,000 mg/day orally)
have been used as endocrine therapy for hormone-related
cancer (27). The plasma steady-state concentration of MPA with
different regimens varied from 1 ng/ml in hormone therapy and
contraception to more than 0.2µg/ml in endocrine treatment of
hormone-related cancer.
It is important to note that the scarce information regarding
the effects ofMPA on immune response hasmostly been obtained
from patients receiving high dose-schedules (28, 29). Studies
carried out in patients receiving high doses of MPA showed
that MPA either suppresses or has no effect on lymphocyte
proliferation stimulated by mitogens (PHA, Con A) (28–30).
High doses ofMPA also reduce the production of IL-1β, IL-6, and
TNF-α of PHA-stimulated peripheral blood mononuclear cells
(PBMCs), providing further evidence that this progestin hinders
the activity of cytokines that play a key role in the pathogenesis
of the anorexia/cachexia syndrome, also explaining the clinical
benefit of MPA treatment in cancer patients with this syndrome
(28). It has been shown that blood mononuclear cells cultured in
MPA at saturating ligand concentration, 10µM (from 2× 104 to
2 × 106 fold higher than in doses found in the serum of MPA
users) produced significantly lower levels of IL-1α, IL-12p40, IL-
10, IL-13, and G-CSF in response to BCG (31). The authors of
this study (31) asserted without showing data that MPA only
inhibited IFN-γ production at high but not at concentrations
equivalent to serum levels in MPA users (31). Others reported
that MPA 10−6 M (at doses 1,000 fold higher than those found in
the serum ofMPA users) inhibited the production of IFN-γ, IL-2,
IL-4, IL-6, IL-12, TNF-α, macrophage inflammatory protein-1α
(MIP-1α) by peripheral blood mononuclear cells and activated
purified CD3+ T (32) MPA also reduced the production of
IFN-α and TNF-α by plasmacytoid dendritic cells in response
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to Toll-like receptor-7,−8, and−9 ligands (32). More recently,
using two different murine Mycobacterium tubercolosis models,
some authors studied the effect of MPA at doses found in serum
of human users. They injected 1mg/ml of Depot (D) MPA and
found concentrations of MPA in the serum of mice from 1 ng/ml
to 23 ± 6.90 ng/ml after 1 week and at 0.19 ng/ml after 16
weeks. They reported that DMPA concentrations altered both
serum TNF-α, G-CSF and IL-10 in C57BL/6 mice and IFN-γ in
BALB/c mice also altering the secretion of IFN-γ, IL-17, GM-
CSF, IL-6, and MCP-1 by mononuclear cells from mediastinal
lymph nodes stimulated byMycobacterium tubercolosis antigens
(PPD or ESAT6) (33). In mice low concentrations of MPA
(10−9M and 10−10M), more similar to the ones found in
the serum of MPA users were unable to induce the secretion
of IL-4 and IL-2 by lymph nodes cells and did not exert a
proliferating effect on lymph node cells of sheep red blood
cells-immunized mice (34), but low dose MPA has the ability
in mice to enhance in vivo and in vitro antibody production
(IgM and IgG) (34).
AHR, is an orphan receptor which mediates the effects
of a large number of synthetic and natural compounds
including halogenated aromatic hydrocarbons like 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) (35). It regulates the
expansion of IL-22-producing cells (Th22 and Th17 cells) and
is involved in the regulation of a number of physiological
processes in many organs, among them all organs of the female
reproductive system (36).
Irregular cycles in AHR knockout mice and TCDD-treated
rats are evidence for a regulatory function of AHR in the estrous
and menstrual cycle (37). Considering that the development
and function of the female reproductive system is mainly
regulated by estrogens and progestins, a crosstalk between the
AHR signaling pathway and sexual steroid hormones is likely.
It has been shown that progesterone increases uterine AHR
levels in rat endometrial epithelium (35), but apparently MPA
does not induce significant changes in AHR transcript levels of
endometrial stromal cells (38).
Interestingly, it was been shown that AHR ligands could have
different effects on T cell-mediated responses. The AHR ligand
TCDD exerts immunosuppressive mediated by AHR effects on
the production of IL-2, IL-4, IL-5, and IL-6, whereas M50364,
a synthetic compound with antiallergic effects increases IFN-γ
but suppresses IL-4 and IL-5 production and the expression of
GATA-3, a key transcription factor for Th2 cell differentiation
(39). The fact that AHR can act on T helper responses suggested
its effects in the development of inflammatory and autoimmune
diseases. In fact TCDD administration confers protection from
Experimental Autoimmune Encephalomyelitis (EAE), inhibiting
Th17 cell differentiation (40). At the time of immunization
systemic application of FICZ, another agonist of AHR, also
reduced EAE pathology albeit to a lesser degree than TCDD.
In vitro Th17 differentiation in the presence of AHR agonists,
including TCDD, promoted IL-17 and IL-22 expression, by Th17
cells but did not induce Treg differentiation.
The role of MPA on human lymphocyte function has been
investigated 1) at higher concentrations of MPA than those
found in the serum of MPA users (28) and, 2) on heterogeneous
populations of peripheral blood and lymph node mononuclear
cells (28, 31, 32, 34, 41). The observed effects of MPA on the
supposed lymphocytes could be mediated by cytokines produced
by a cell type present in the mononuclear cell fraction in response
to MPA and not by the direct effect of MPA on T cells. We
designed a study to examine the direct effect of MPA on human
T CD4+ cells at concentrations equivalent to those found in
serum of MPA users from 6 months to 9 months following
administration [from 0.2 to 0.02 ng/ml (28)]. We determined
the effect of MPA on the proliferation, production and mRNA
expression of IFN-γ, IL-5, IL-10, IL-4, IL17, and IL-22 of human
established CD4+ T cell clones, which cannot be contaminated
by other cells present in the PBMC fractions and on Th2-, Th1-
, Th22, and Th17-specific transcription factors (GATA 3, T-bet,
AHR, ROR-C, respectively) mRNA expression. For the first time
the effect of MPA on IL-22 and AHR expression by T helper cell
subpopulations has been investigated.
MATERIALS AND METHODS
All the methods used for the study were performed in accordance
with the relevant guidelines and regulations.
Donors
Twenty-seven healthy donors of peripheral blood agreed to
participate to the study at AOU Careggi, Florence, Italy. They
received verbal and written information about the aim and
the design of the research, and all donors signed the informed
consent and the study was approved by local ethic committee of
AOU Careggi (n.115303). The 27 donors (age mean ± SD; 29.9
± 0.9 years) were male (14) (mean age ± SD; 30.5 ± 4.2 years)
and female (13) (mean age ± SD; 29.8 ± 4.1 years). There were
no significant age differences between the groups of male and
female donors. Donors who were enrolled had normal body BMI
and had negative results for illnesses (infections, autoimmune
and inflammatory diseases), exposure to communicable diseases,
travel to disease endemic areas, pregnancy and lactation, medical,
and surgical interventions, history of recent infections, currently
under the influence of alcohol or drugs, or undergoing therapy
with hormonal or anti-inflammatory therapy in particular.
REAGENTS
PHA was purchased from GIBCO Laboratories (Grand Island,
N.Y.) and phorbol 12-myristate 13-acetate (PMA) from
Sigma Chemical Co. (St. Louis, MO). OKT3 (anti-CD3) mAb
was purchased from Ortho Pharmaceuticals (Raritan, N.J.).
Anti-CD4, anti-CD8 were obtained from Becton-Dickinson
(Mountain View, Ca). Human recombinant IL-2 was a generous
gift of Eurocetus (Milano, Italy). Human recombinant IL-12
was obtained from RD systems (Minneapolis, MN). FCS
was from HyClone Lab Inc. (Logan, UT). 3H-thymidine was
from Amersham (Buckinghamshire, UK). Highly purified
MPA (6α-methyl-17α-hydroxyprogesterone acetate) and
Mifepristone were purchased from Sigma Aldrich (St. Louis,
MO). Streptokinase (SK) was purchased from Aventis Behring
GmbH (Germany).
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Generation of T Cell Clones
To generate T-cell clones, peripheral blood mononuclear cells
(PBMCs) of normal subjects were seeded under limiting dilution
conditions (0.3 cell/well) in 6 round-bottomed microwell plates
containing 105 irradiated (9,000 rad) allogeneic PBMC (as feeder
cells) and PHA (1% vol/vol) in a final vol of 0.2ml complete
medium supplemented with IL-2 (50 U/ml) and 10% FCS,
as reported elsewhere (6). Growing microcultures were then
supplemented, at weekly intervals, with IL-2 (50 U/ml) and
105 irradiated feeder cells. The phenotype distribution of T-cell
clones was assessed by flow cytometer analysis.
Proliferation of T Cell Clones Stimulated by
Immobilized Anti-CD3 Antibodies in the
Absence and in the Presence of MPA
2 × 105 T cell blasts obtained from 7 CD4+ T cell clones,
able to produce IL-4, IL-5, IL-13, IL-10, IFN-γ, IL-17A,
IL-17F, IL-22, in 0.2ml RPMI 1640 medium supplemented
with 2mM L-glutamine, 2 × 10−5 M 2-mercaptoethanol and
10% FCS (Hyclone Laboratories Inc., Logan, UT) (complete
medium) were stimulated in 96 U-bottomed plates with
immobilized anti-CD3 antibodies in the absence or in the
presence of MPA (0.02, 0.2 and 2 ng/ml) for 5 days. These
concentrations were chosen on the basis of those found in
the serum during contraception and HRT (26). After a 16-
h pulse with 0.5 µCi 3H-TdR (Amersham International),
cultures were harvested and radioactivity measured by
liquid scintillation.
Proliferation of PBMCs Stimulated by SK in
the Absence and in the Presence of MPA
2 × 105 PBMCs of 5 donors in 0.2ml of complete medium in 96
U-bottomed plates were stimulated for 5 days with PHA and the
antigen Streptokinase (SK) (500U.I./ml) in the absence or in the
presence of MPA (0.02, 0.2, and 2 ng/ml) for 5 days. After a 16-h
pulse with 0.5 µCi 3H-TdR (Amersham International), cultures
were harvested and radioactivity measured by liquid scintillation.
Induction of Cytokine Production by T Cell
Clones in the Absence and in the Presence
of MPA
To induce cytokine production, 2 × 105 T blasts from each 23
CD4+ T cell clone were cultured in the presence of immobilized
anti-CD3 mAb (10µg/ml) in the absence or the presence of
MPA (0.02 and 0.2 ng/ml). After 36 h, culture supernatants were
collected, filtered, and stored in aliquots at−70◦C until used. For
mRNA determination the cells were collected after 6 h.
Induction of the Cytokine Production of
PBMCs Stimulated by SK in the Absence
and in the Presence of MPA
2 × 105 PBMCs obtained from 15 donors in 0.2ml of complete
medium in 96 U-bottomed plates for 5 days were stimulated with
the antigen (SK 500U.I./ml) in the absence or in the presence
of MPA (0.02 and 0.2 ng/ml). After 5 days supernatants were
collected and stored in aliquots at−80◦C until used.
Induction of Cytokine Production of
Macrophages Stimulated by SK in the
Absence and in the Presence of MPA
106 monocytes obtained from 7 donors were purified by
adherence from PBMCs (mean ± SD; 92.59 ± 2.51%) in
1ml of complete medium in 96 U-bottomed plates for 5
days with the antigen SK (10µg/ml) in the absence or in
the presence of MPA (0.02, 0.2, and 2 ng/ml). After 5 days
supernatants were collected and stored in aliquots at −80◦C
until used.
Total RNA Extraction and Real Time
Quantitative RT-PCR IL-4, IL-13, IL-5,
IFN-γ, GATA-3, T-bet, IL-17, IL-22, ROR-C,
AHR, and β-actin
Total RNA was extracted with RNAsy Kit and treated with
DNase I (Qiagen, Hilden Germany) from 5 CD4+ T cell clones,
and PBMC from 5 donors. cDNA was synthetized by using
TaqMan Reverse Transcription Reagents (Applied Biosystem,
Warrington, United Kingdom). Reverse Transcription–
Polymerase Chain Reaction (RT-PCR) was then performed
by using TaqMan methodology as described elsewhere (42).
Quantitative analysis of IL-4, IFN-γ, IL-10, IL-13, IL-5, GATA-3,
T-bet, IL-17, IL-22, ROR-C, AHR, and β-actin was performed
by using Assay on Demand (Applied Biosystem, Warrington,
United Kingdom). β-actin was used for normalization.
Quantitation of Cytokine Production by
CD4+ T Cell Clones
The quantitative determination of IL-1beta, IL-1RA, IL-2, IL-
4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17A,
IFN-alpha, TNF-alpha, G-CSF, GM-CSF, VEGF, PDGF, FGF,
IP-10, MCP-1, RANTES, eotaxin, MIP-1-alpha, and MIP-1-
beta was performed by a bead-based multiplex immunoassay
(Biorad Laboratories, Hercules, CA). IL-17A, IL-17F, IL-
21 and IL-22 were measured by a bead-based multiplex
immunoassay (R&D, Minneapolis, MN) and a Bioplex 200
system (Biorad Laboratories, Hercules, CA) as we previously
described (43, 44).
Statistical Analysis
Statistical analyses were performed using SPSS software
(SPSS, Inc, Evanston, IL). Due to non-parametric distribution,
all comparisons between cytokine concentrations in basal
and stimulated conditions were performed by Wilcoxon
test. Data are reported as median and ranges unless
otherwise stated.
RESULTS
Effect of MPA on the Proliferation and on
the Cytokine Profile of Peripheral Blood
Mononuclear Cells (PBMCs)
We used PBMCs to mimic in vitro a T cell specific response
to an antigen derived from a pathogen. We investigated the
effect of MPA when the antigen presenting cells in the PBMC
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fraction present an antigen to T cells and activate these T
cells. Streptokinase (SK), a highly purified antigen extracted
from a C-group beta-hemolytic streptococci culture and devoid
of all other metabolic products of streptococci, was used
as antigen.
Unstimulated PBMCs from 5 normal donors cultured in the
presence of MPA at 0.02, 0.2, and 2 ng/ml showed no significant
differences in their proliferative response compared PBMCs
cultured in medium alone (data not shown).
Streptokinase (SK)- stimulated PBMCs from 5 donors in
the presence of MPA at 0.02, 0.2, and 2 ng/ml showed no
significant differences in their proliferative response compared
to SK-stimulated PBMCs expanded in the absence of MPA (data
not shown).
To provide evidence of the effect of MPA on PBMCs, we
analyzed the ability of MPA to act on Th2-type cytokines
(IL-4, IL-5, and IL-13), Th1-type cytokine (IFN-gamma) and
Th17-type cytokines (IL-17A, IL-17F, and IL-22) production
(Figure 1) by PBMCs from 10 different donors. There was no
statistical difference in PBMCs cytokine production when cells
were cultured without any stimulation in medium alone and in
medium+MPA at 0.02, 0.2, and 2 ng/ml (data not shown).
The effects of SK stimulation alone over medium were
not statistically significant for IL-4, IL-5, IL-13, IL-22, and
IL-17F production in PBMCs, but significant for IFN-γ and
IL-17A (Figure 1).
When PBMCs were stimulated with SK in the absence
or presence of MPA, the levels of IFN-γ, IL-5, IL-13, IL-
17A were significantly decreased whereas the levels of IL-
22 were significantly increased in the presence of MPA
compared to those found in the absence of MPA (Figure 1),
indicating that MPA seems to modulate T cell cytokine
production regardless the amplitude of the effect of SK
alone. Thus, MPA seems to modulate the T cell cytokine
production only after the stimulation of T cells by an antigen
(here SK) presented by the antigen presenting cells in the
PBMCs fraction.
We also attempted to confirm the previous results by
examining with real time RT-PCR analysis of PBMCs of 5
additional donors stimulated with SK in the absence or in
the presence of 0.02 and 0.2 ng/ml of MPA (Figure 2). As a
control, the PBMCs were also stimulated with SK in the presence
of IL-12, a potent inducer of Th1 differentiation (45). We
found a significant increase of IFN-γ (p = 0.043) (Figure 2)
in response to IL-12, suggesting that the culture conditions
were satisfactory for the modulation of the PBMCs. PBMCs
expressed lower levels of mRNA for IL-5, IL-13, IFN-γ, IL-
17A and its transcription factor ROR-C (Figure 2). Higher
levels of mRNA were found for IL-22 and the corresponding
transcription factor AHR (Figure 2) when MPA was added to
the culture medium. mRNA levels for IL-4 were not modified by
MPA (Figure 2).
These results indicate that MPA can decrease some Th2-
type cytokines (IL-5 and IL-13, but not IL-4), including a Th1
cytokine (IFN-γ) and a Th17-type cytokine (IL-17A). However,
MPA increases IL-22, which can be produced by Th22 and
Th17 cells.
Effect of MPA on the Cytokine Profile of
Macrophages Derived From Peripheral
Blood Monocytes
The negative effect of MPA on Th1, Th2, Th17-type cytokine
production of PBMCs and its positive effect on Th22-type
cytokine production could be due to the modulating effect
of MPA on APCs present in the microenvironment of the
T cells. However, the levels of these cytokines produced by
SK-stimulated macrophages cultured in the presence of MPA
were not significantly different than those of SK-stimulated
macrophages cultured in the absence of MPA (Figure 3). Thus, in
PBMC fractions the negative effect of MPA on Th1, Th2, Th17-
type cytokine production of PBMCs and its positive effect on
Th22-type cytokine production seem to be due to the action of
MPA directly on T cells.
Moreover, cytokine production by macrophages in response
to MPA could in turn modulate the T cell cytokine production.
The negative effect of MPA on T cell-IFN-γ-production was
not due to a decreased production of IL-12 and/or IFN-
α and/or IL-18 by macrophages treated with MPA, i.e., the
concentrations of IL-12, IFN-α, TNF-α, and IL-18 produced by
purified macrophages from 7 different donors stimulated with
SK showed no significant differences when cells were cultured
either in the absence or in the presence of MPA (Figure 5). Thus,
MPA acts directly on CD4+ T cells to decrease IFN-γ production
and mRNA expression (Figures 1, 2). However, the levels of IL-
1α and IL-6 produced by SK-stimulated macrophages cultured in
the presence of MPA (2 ng/ml) (data not shown) and the levels
of MIP-3α (CCL20) in the presence of MPA at 0.02, 0.2, ng/ml
(Figure 3) and 2 ng/ml (data not shown) were lower than those
of SK-stimulated macrophages cultured in the absence of MPA.
The decreased production of IL-1α and IL-6 by macrophages in
response to MPA at 2 ng/ml, i.e., at a concentration higher than
found in the serum of women treated with MPA after 6 and 9
months, was reported at 200 ng /ml (28). MIP-3α is the known
ligand of CCR6, which is expressed on the cell membrane of Th17
cells. The interaction CCR6/CCL20 contribute to the trafficking
of Th17 cells. Thus, the reduction of IL-17 production by T cells
in the presence of MPA at doses found in the serum of human
users could be associated with a reduction of the trafficking of
Th17 cells. The levels of IL-23 essential for development of Th17,
produced by SK-stimulated macrophages were not modified by
the presence of MPA suggesting that MPA acts directly on CD4+
T cells by decreasing IL-17 production.
Direct Effects of MPA on the Proliferation
and on the Cytokine Profile of Established
CD4+ T-Cell Clones
To investigate the direct effect ofMPA on the proliferative activity
of unstimuled purified T cells, 7 T cell clones in medium alone
and in medium plus MPA at 0.02, 0.2 and 2 ng /ml were analyzed
for their ability to proliferate. No statistical difference of the T cell
clones proliferative response was found when cells were cultured
without any stimulation in medium alone and in medium plus
MPA at 0.02, 0.2, and 2 ng/ml (data not shown).
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FIGURE 1 | Effect of MPA on the cytokine profile of peripheral blood mononuclear cells (PBMCs). PBMCs from 10 different donors were stimulated with SK in the
absence or presence of MPA at 0.02 and 0.2 ng/ml to provide their ability to modulate Th2-type cytokine (IL-4, IL-5, IL-13), Th1-type cytokine (IFN-gamma) and
Th17-type cytokines (IL-17A, IL-17F, and IL-22) production.
The direct effect ofMPA on the proliferative activity of CD4+T
cell clones stimulated with immobilized anti-CD3 antibody in
the absence or presence of MPA at 0.02, 0.2, and 2 ng/ml was
analyzed. According to the results obtained with PBMCs, no
significant differences in the proliferative response were observed
between stimulated T cell clones expanded in the presence or in
the absence of MPA (data not shown).
To provide evidence of the direct effect of MPA on CD4+T
helper cells, we examined the ability of MPA to act on a panel
of cytokines (as listed in Methods). We also studied MPA effects
on IFN-γ, IL-5, IL-4, IL-13, IL-17A, IL-22, and IL-10 mRNA
expression by established CD4+ T-cell clones. Thirteen CD4+ T-
cell clones were cultured in the presence of recombinant human
IL-12, a Th1 inducer, which acts as a control of the functional
activity of T cell clones. When the 13 CD4+ T-cell clones were
cultured with IL-12, the levels of IFN-γ and mRNA for IFN-γ
increased (Figures 4A,B) (p = 0.02 and p = 0.005, respectively)
suggesting that the culture conditions were satisfactory for the
modulation of CD4+ T cell clones.
There was no statistical difference between the T cell clones
cytokine production when cells were cultured without any
stimulation in medium alone or in medium plus MPA at 0.02,
0.2, and 2 ng/ml (data not shown).
When Thirteen CD4+ T-cell clones were cultured in the
absence of any other cell type and stimulated with insolubilized
anti-CD3 monoclonal antibody in the absence or presence of
MPA the levels of IL-1beta, IL-1RA, IL-2, IL-6, IL-8, IL-9, IL-10,
IL-12, IL-15, IL-17F, TNF-α, G-CSF, GM-CSF, VEGF, PDGF, FGF,
IP-10, MCP-1, RANTES, eotaxin, MIP-1-α, MIP-1-β, IL-21 (data
not shown), IL-22, and IL-4 (Figure 4A), were not significantly
modified in the presence of MPA. In contrast, the levels of
IFN-γ, IL-5, IL-13, IL-17A were significantly decreased in the
presence ofMPA compared to those found in the absence ofMPA
(Figure 4A). Thus, MPA seems to modulate the T cell cytokine
production of T cells only when these cells are stimulated.
Real time RT-PCR analysis was used to determine MPA
influence on IFN-γ, IL-5, IL-13, IL-17A, IL-4, IL-22, GATA-3 (a
Th2-specific transcription factor) (46, 47) T-bet (a Th1-restricted
transcription factor) (48), ROR-C (a Th17-specific transcription
factor) and AHR (a transcription factor expressed by Th22 cells)
mRNA expression of the CD4+T cell clones stimulated with
immobilized anti-CD3 monoclonal antibody without or with
MPA (Figure 4B). CD4+ T cell clones were also stimulated with
immobilized anti-CD3 antibodies in the presence of IL-12. We
confirmed an increase of IFN-γ in response to IL-12, suggesting
that the culture conditions were satisfactory for the modulation
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FIGURE 2 | Effect of MPA on the cytokine profile and transcription factor expression by peripheral blood mononuclear cells (PBMCs). mRNA expression of IL-4, IL-5,
IL-13, IL-17A, IFN-γ, IL-22, AHR, and RORC performed by RT-PCR analysis of the PBMCs from 5 donors stimulated with SK in the absence or in the presence of
0.02 and 0.2 ng/ml of MPA was analyzed. PBMCs were also stimulated with SK in the presence of IL-12, which is a potent inducer of Th1 differentiation, to ensure
that the culture conditions were satisfactory for modulation of the cytokine production of CD4+ T cell clones.
of CD4+ T cell clones (Figure 4B). The CD4+ T cell clones
expressed lower levels of IFN-γ, IL-5, IL-13, IL-17A, ROR-C, and
T-bet mRNA in the presence of MPA compared to the control,
whereas the levels of transcripts for IL-4 and GATA-3 were not
modified by the presence of MPA in the culture but the levels of
AHR increased (Figure 4B).
Surprisingly, we found that the levels of IL-22 were
increased when MPA is added to cultures of PBMCs, but not
when it is added to the CD4+ T cell clones, although the
levels of m RNA for AHR the transcription factor of Th22
cells producing IL-22 expressed by the same T cell clones
were increased.
This apparent paradox could be explained by the fact that
IL-22 is not only produced by Th22 cells, but also by Th17
cells, and there could be a differential production of IL-22 by
Th17 and Th22 cells in response to MPA. AHR could be the
key factor explaining the effect of MPA on the T cells. To
investigate this possibility, we studied the effects of MPA on
the cytokine profile of established CD4+ Th1- Th2-Th-17 and
Th22-cell clones.
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FIGURE 3 | Effect of MPA on the cytokine profile of macrophage. Macrophages from PBMC obtained from 7 donors purified by adherence stimulated for 5 days with
the antigen SK in the absence or in the presence of MPA (0.02, 0.2, and 2 ng/ml). IL-1α, IL-6, TNF-α, IFN-α, IL-12, IL-18, IL-23, MIP3α, IL-10, IL-4, IL-5, IL-13 IL-17A
IFN-γF, and IL-22 were measured in the supernatants.
Direct Effects of MPA on the Cytokine
Profile of Established CD4+ Th1- Th2-Th17
and Th22-Cell Clones
To verify the direct effect of MPA on the different CD4+T
cell subpopulations, 6 Th1 clones, 6 Th2 clones, 6 Th17/Th1
clones and 6 Th22 clones were stimulated with insolubilized anti-
CD3 monoclonal antibody in the absence or presence of MPA
(Figures 5A,B) and at protein level analyzed for IL-4, IL-5, IL-13,
IL-22, IL-17A, IFN-γ. mRNA levels were determined for AHR,
ROR-C, and T-bet.
In the presence of MPA levels of IL-4, IL-5, IL-13, IL-22,
IL-17A produced by Th1 cells were not significantly modified.
In contrast, the levels of IFN-γ produced by Th1 cells were
significantly decreased in the presence ofMPA compared to those
found in the absence of MPA (Figure 5A).
The levels of IL-4, IFN-γ, IL-22, IL-17A produced by the Th2
cells were not significantly modified in the presence of MPA.
However, the levels of IL-5 and IL-13 produced by Th2 cells were
significantly decreased in the presence ofMPA compared to those
found in the absence of MPA (Figure 5A).
The production of IL-4 (data not shown), IL-5 (data
not shown), IL-13, AHR and T-bet mRNA expression by
Th17/Th1 cells were not significantly modified in the presence
of MPA. Levels of IFN-γ, IL-22 and IL-17A at protein and
mRNA levels (data not shown), and mRNA for ROR-C
expressed by Th17/Th1 cells were significantly decreased in the
presence of MPA compared to those found in the absence of
MPA (Figure 5B).
The levels of IL-4, IL-5 (data not shown), IL-13 (data not
shown), IFN-γ and IL-17A produced by the Th22 cells were not
modified whereas the levels of mRNA for AHR, T-bet and IL-22,
as well as levels of IL-22 protein (p = 0.042) were significantly
increased in the presence of MPA compared to those found in
the absence of MPA. Moreover, the levels of mRNA for ROR-C
were not modified in Th22 cells in presence of MPA compared to
those found in absence of MPA (Figure 5B).
These data confirmed the negative effects of MPA on the
production of IFN-γ, IL-5, IL-13, and IL-17A, but supported the
finding that Th17 and Th22 cells, which are able to produce
IL-22, react differently to MPA; IL-22 production in response
to MPA is increased in Th22 cells and decreased in Th17
cells. This could explain why the statistical analysis of IL-22
production by 13 different T- cell clones derived from different
Th type subpopulations does not appear to be influenced byMPA
(Figure 4A). The increased production of IL-22 by Th22 cells is
probably compensated by the decreased production of IL-22 by
the Th17 cells in response to MPA. Moreover, it seems that T-bet
and AHR control the production of IL-22 by Th22.
DISCUSSION
We found that therapeutic concentrations of MPA, comparable
to those present in the serum of women undergoing HRT or
contraception, have no effect on the proliferation of CD4+ cells
and several cytokines, (IL-1beta, IL-1Ra, IL-2, IL-4, IL-6, IL-8, IL-
9, IL-10, IL-12, IL-15, IL-17F). Neither do these doses of MPA
Frontiers in Immunology | www.frontiersin.org 8 April 2019 | Volume 10 | Article 642
Piccinni et al. MPA Affects T-Cell Responses
FIGURE 4 | Direct effects of MPA on the cytokine profile of established CD4+ T-cell clones. IL-4, IL-5, IL-13, IL-17A, IFN-γ, IL-17F, and IL-22 production were
measured in the supernatant of 13 established T-cell clones (TCC) by multiplex assays (A). mRNA expression for IFN-γ, IL-5, IL-4, IL-13, IL-17A, IL-22, GATA3, T-bet,
and AHR was examined (B). As a control, the 13 CD4+ T cell clones were also stimulated with immobilized anti-CD3 antibodies in the presence of IL-12, a potent
inducer of Th1.
affect TNF-α, G-CSF, GM-CSF, VEGF, PDGF, FGF, IP-10, MCP-
1, RANTES, eotaxin, MIP-1α, MIP-1β or IL-21 production by
CD4+T cells. In contrast, MPA specifically decreases IFN-γ, IL-
5, IL-13 and IL-17A production but increases IL-22 production
by CD4+ T cells. These results were confirmed by examining
MPA effects on mRNA levels. Furthermore, MPA decreased not
only IL-17A production by Th17 cells but also MIP-3α (CCL20)
by macrophages, which contributes to decreased trafficking of
Th17 cells.
Interestingly, IL-22 production is decreased in Th17 cells
treated with MPA but increased in Th22 cells. The decreased
production of IL-17A and IFN-γ in the presence of MPA is
associated with the decreased expression of ROR-C and T-bet,
respectively, whereas the increased production of IL-22 by Th22
cells is associated with the increased expression of T-bet and AHR
in response to MPA.
Thus, MPA, at doses equivalent to those found in the serum of
women using MPA for contraception or HRT, could influence T
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FIGURE 5 | Direct effects of MPA on the cytokine profile of established CD4+ Th1- Th2-Th-17 and Th22-type T cell clones (TCC). To provide evidence of the direct
effect of MPA on different CD4+T cell subpopulations, 6 CD4+ Th1 T-cell clones, 6 CD4+ Th2 T-cell clones, 6 CD4+ Th17/Th1 T-cell clones and 6 CD4+ Th22 T-cell
clones were stimulated with insolubilized anti-CD3 monoclonal antibody in the absence or presence of MPA at 0.2 ng/ml. The levels of IL-4, IL-5, IL-13, IL-17A, IFN-γ,
and IL-22 were measured by multiplex assays in the supernatants (A) and of mRNA for AHR, RORC, and Tbet by RT-PCR (B).
cell immune responses toward allograft rejection, infections and
asthma as demonstrated in vivo in humans (49–56).
Indeed, an allograft rejection is characterized by a
predominant production of IFN-γ (57, 58). Our results
showing the depressed production of IFN-γ in response to
MPA are consistent with data from animal model studies
indicating that MPA prolongs survival of skin and renal
allografts (49, 59, 60). More interestingly, in a trial of humans
with intrafamilial renal transplants treated by addition of MPA to
the immunosuppressive regimen, when renal function was stable
at the time of initiation of MPA therapy, prednisone dosage
could be lowered to an average of 37% of the previous dose
(49). Thus, MPA has been shown to have immunosuppressive
functions in human.
IFN-γ also plays an important role in adaptive and innate
immune responses to viral and intracellular bacterial infection
(61). The decreased IFN-γ production by T cells in response
to therapeutic concentrations of MPA suggests this synthetic
progestin could influence antiviral immunity. In fact, MPA
is used to increase infectibility in mouse models of sexually
transmitted diseases (62). Relative to progesterone, MPA was
shown in these models to increase by ten-fold susceptibility
to infection by Herpes simplex virus type 2 (HSV-2) (62).
Unlike progesterone, MPA significantly decreases the immune
response to intracellular pathogens (63). A Th1 response
seems to be protective against HSV viral spread and tissue
damage, but shifting to a Th2 response is associated with
resolution of immunopathology (64, 65). MPA, by decreasing
IFN-γ production by T cells, could be, at least in part,
responsible for an increased susceptibility to infection by Herpes
simplex virus. More importantly, it was reported that consistent
MPA contraceptive use in 682 HSV2-negative women induced
increased risk of HSV-2 seroconversion. In fact, incidence rate
was 13.5 per 100 person-years in women consistently using
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FIGURE 6 | Effect of MPA on the cytokine profile of established CD4+ Th1, Th2, Th17, and Th22 cells: summary of identified changes and potential outcomes.
Therapeutic concentrations of MPA, comparable to those present in the serum of women undergoing HRT or contraception, decreases IFN-γ, IL-5, IL-13, and IL-17A
production but increases IL-22 production by CD4+ T cells. Thus, MPA by decreasing IFN-γ by Th1 cells could diminish the T cell immune responses to intracellular
pathogens (viruses); by decreasing IL-5, MPA could diminish the T cell immune responses to helminths; by decreasing IL-13 could affect allergic disorders; by
decreasing IL-17A, MPA could diminish the T cell immune responses to extracellular pathogens; and by increasing IL-22 by Th22 cells MPA may contribute to the host
defense against microbial pathogens, in addition to promoting tissue repair or remodeling.
DMPA (nine incident infections per 66.5 person-years) and 6.6
per 100 person-years in women who were neither pregnant
nor using hormonal contraception (35 incident infections per
529.5 person-years) (52). Very recently, an updated systematic
review incorporate studies published between January 2009 and
June 2017. Thirty articles met the inclusion criteria and showed
that Depo-medroxyprogesterone acetate (DMPA) increased the
risk of HSV-2 (strong effect, few studies), whereas data on oral
contraceptive use suggested it was associated with inconclusive
findings for HSV-2 (53).
A Th1/Th2 cytokine imbalance is also critical to HIV-1
progression and pathogenesis. It was shown that addition of
exogenous IFN-γ mediates antiviral activity against R5 HIV-
1 thymocytes, which decreases viral replication in infected
thymocytes (66). It was suggested that MPA suppresses both
innate and adaptive arms of the immune system resulting in
a reduction of host resistance to invading pathogens as HIV-
1 (32). However, MPA was used in culture at doses 1,000 fold
higher than the those found in the serum of MPA users. In
the present study we show for the first time that doses of
MPA equivalent to those found in women actually using MPA
decrease IFN-γ production by T cells, which could influence
HIV progression. Thus, MPA, by increasing shedding of HIV-
1 DNA (67), increases the HIV transmission risk, and, by
decreasing IFN-γ production by T cells, may also influence HIV
viral replication. There is now a major concern in women who
use long acting injectable hormonal contraceptives, particularly
Depo-MPA with an increase of HIV-1 risk acquisition. In fact,
different recent meta-analyses showed a significant association
between use of Depo-MPA and the presence or acquisition
of HIV+ in women (54–56). For this reason, the World
Health Organization (WHO) published guidelines for hormonal
contraceptive eligibility for women at high risk of HIV in March
2017. The guideline development group, through a consensus,
made recommendations to change the medical eligibility criteria
for contraceptive use from category 1 (condition for which there
is no restriction for the use of the contraceptive method) to
category 2 (condition where the advantages of using the method
generally outweigh the theoretical or proven risks) for Depo-
MPA among women at high risk of HIV acquisition (68).
It is important to recognize that MPA is the most commonly
used progestin in the USA and Europe for hormone replacement
therapy (23). In addition, MPA is the most widely used injectable
female contraceptive (21), with at least 20 million current
users worldwide (22). Of special interest in the developing
world, with its high incidence of viral diseases and endemic
malnutrition, we suggest that the choice of synthetic progestins
used in contraception could have important implications for
viral disease development. It is important to note, however, that
the use of hormonal contraceptives, and in particular of MPA,
does not significantly impact the effectiveness of antiretroviral
therapy (25, 69).
As progesterone can induce an increased production of IL-5
and IL-4 by T cells, yet have no effect on T cell IFN-γ production
(6), MPA is the only progestin yet analyzed that influences IFN-
γ production by Th1 cells when used as a contraceptive or
for HRT and also decreases IL-5 and IL-13 production without
affecting IL-4 production. As a result of this activity MPA
may also have an influence on allergic responses. Allergy is
a disorder characterized by an increased ability of B cells to
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produce IgE in response to certain groups of ubiquitous antigens
(allergens) that can activate the immune system after inhalation,
ingestion or penetration through the skin. IgE antibody synthesis
results from the collaboration between Th2 cells and B cells,
in which CD40/CD40L interaction is required (70). IL-4 and
IL-13 produced by Th2 cells induce the production of IgE
by B cells whereas Th1 cells produce IFN-γ that suppresses
IgE synthesis (71). Th2 cells also produce IL-5 that favors the
differentiation, activation and survival in situ of eosinophils.
MPA by acting to decrease IL-5, IL-13 and IFN-γ production
by T cells could have a negative effect on the differentiation
of eosinophils, their activation and survival while having a
positive effect on IgE production induced by IL-4. The latter
activity would decrease the negative effect of IFN-γ on the
IgE production. Asthma is a complex disorder characterized
by intermittent, reversible airway obstruction, and by airway
hyperresponsiveness and inflammation. Asthma may be divided
into allergic (extrinsic) and non-allergic (intrinsic) asthma. Both
allergic and non-allergic asthma are characterized by the presence
in the bronchial mucosa of large numbers of activated eosinophils
and of elevated concentrations of eosinophil-derived proteins,
such as major basic protein and eosinophil cationic protein (72).
In allergic asthma, the importance of Th2 cytokines, especially
IL-5, in the induction of allergic pulmonary inflammation and
airway hyperreactivity has been reported (73). Corticosteroid
treatment in asthma, is associated in the downregulation of
BAL cells expressing mRNA for IL-4 and IL-5 and in the
upregulation of cells expressing mRNA for IFN-γ (74). MPA
decreases IL-5 and IL-13 production and mRNA expression by
T cells. This suggests that widely used concentrations of MPA
can have a positive influence on the health status of patients with
allergic and non-allergic asthma by decreasing IL-5 production
by T cells, thus reducing eosinophilic infiltration of the lungs.
Interestingly, after 6 months of HRT with transdermal 17-
beta-estradiol and MPA, diminishing symptoms of asthma were
observed and there was a reduction in the number of patients
in whom it was necessary to use oral glucocorticoid therapy
during exacerbation of asthma (50, 51). These patients were
treated with 17-beta-estradiol associated withMPA.However, the
diminishing symptoms of asthma cannot be due to the estradiol,
which potentiates the development of asthma. In fact, in male
mice treated with estradiol, eosinophil numbers increase in both
blood and airways and the production of IL-5 and IL-13 by T
cells is promoted (75). Thus, estradiol increases IL-5 produced
by T cells, whereas MPA decreases IL-5. Therefore, the reduced
asthmatic symptoms in patients treated with 17-beta-estradiol
and MPA could be due to the reduction of IL-5 production
mediated by MPA.
We found that MPA at therapeutic concentrations found in
the serum of women upregulates AHR. AHR plays important
physiological roles in many cells of the immune system, notably
the Th17 and Th22 cells (76–78). Most of the current literature
on AHR effects on immune system function is focused on
the consequences of exposure to the high affinity ligand 2,
3, 7, 8 tetrachlorodibenzo-p-dioxin (TCDD). However, many
recent studies in mice lacking AHR expression indicate that
AHR activation affects important physiological functions in
the absence of xenobiotic ligands (79). There is a range of
potential physiological ligands for AHR including diet-derived
AHR ligands (Quercetin present in apples and onions, Indol-3-
carbinol present in many Brassicaceae, Resveratrol present in red
wine, Curcumin), which strongly influence intestinal immune
parameters (79). Our data seem to suggest that MPA could be
another ligand for AHR. In agreement with the hypothesis that
steroid hormones could affect AHR expression and could be
a ligand of AHR, it was demonstrated that progesterone, as
well as 17-beta-estradiol, regulate the AHR battery homeostasis
in the rat uterus (37). Progesterone leads to an increase in
uterine AHR levels, especially in endometrial epithelium. Only
one demonstration of MPA influence on endometrial but not
T cells showed that no significant changes were observed in
AHR transcript levels in endometrial cells (35). While these
results indicate that female sexual steroid hormones regulate
the expression of the AHR battery in organs of the female
reproductive system, no effectiveness of female hormones, in
particular MPA, on the expression of the AHR battery in T cells
has been previously reported.
The present study show that MPA, at concentrations found
in the serum of women undergoing contraception or HRT, up-
regulates IL-22 production by CD4+ Th22 cells through AHR
and T-bet -induced signals, whereas IL-22 production by Th17
cells is down-regulated and Tbet and AHR are not modified by
MPA. These data suggest that the differential production of IL-
22 by Th22 cells and Th17 cells by MPA could be carried out
through AHR-induced signals and T-bet-induced signals. In fact,
it appears that IL-22 expression is due to the cooperation of AHR
and T-bet-induced signals (78).
The ligand dependant-AHR activity is involved in the
regulation of T cell-mediated immune responses (76, 77)
and, as such, could be involved in shaping the course of
autoimmune pathology. This suggest a link to environmental
factors containing ligands of AHR that influence autoimmune
disease. AHR-deficient mice developed a much milder form
of EAE with many of these mice altogether protected from
the onset of disease (76). However, the application of AHR
agonists caused differential effects. The administration of the
tryptophan metabolite 6-formylindolo(3,2-b) carbazole (FICZ),
an endogenous AHR agonist, exacerbated disease (76), while
systemic administration of TCDD had the same ameliorating
effect on disease progression as AHR-deficiency (77). This
led to the suggestion that AHR exerts its effects on immune
responses in a ligand-dependent manner. The differential effects
of different AHR agonists on autoimmune disease progression
is probably due to their influence on the T helper responses
responsible for the disease progression (39). Indeed, it has
been demonstrated that the oral administration of a synthetic
compound M50354, a AHR agonist, reduces the production
of IL-4 and IL-5 by Ag-stimulated splenocytes and enhances
the production of IFN-γ. TCDD, another AHR ligand, exerts
suppressive effects on the production of IL-2, IL-4, IL-5, and IL-
6. In contrast, M50367 did not affect the production of IL-2 and
IL-6, but appeared to reduce Th2-mediated immune responses.
M5037 suppressed the expression of a key transcription factor
for Th2 cell differentiation, GATA-3, and the production of IL-4,
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although it is not known whether activated AHR is directly
involved in GATA-3 expression (39).
These data suggest that AHR may play an important role in
the normal development and function of the immune system
by down-regulating IFN-γ. In agreement, we showed that MPA
has no effect on IL-4, upregulates AHR, downregulates IFN-γ
production by T cells. Moreover, it was shown that in response to
OVA immunization, high levels of IFN-γ mRNA were detected
in lymphocytes from AHR Knock-out (AHR-/-) mice, but IL-4
mRNA levels in AHR-/- cells were similar to those in AHR+/+
mice (80).
The effects of AHR agonists on IL-22 production have
been reported (81). AHR is down-regulated in intestinal tissue
of patients with IBD; and AHR signaling via IL-22 inhibits
inflammation and colitis in the gastrointestinal tract of mice (81).
Intestinal lamina propria mononuclear cells in the presence of
FICZ showed reduced levels of IFN-γ and up-regulated levels
of IL-22 (81). We showed that MPA downregulates IFN-γ and
upregulates AHR and IL-22 expression and production by T cells
as does FICZ, the agonist of AHR.
Our results allow us to speculate that MPA could be an
agonist of AHR in T cells, acting to decrease IFN-γ and, at the
same time, IL-17A, upregulating IL-22 without any effect on
IL-4 production.
It is important to note that AHR acts as an important co-
factor in infections. For instance, AHR-deficient mice infected
with Listeria monocytogenes, an intracellular bacterium, were
more susceptible to infection but developed enhanced resistance
to re-infection (82). Depending on the cell context analyzed and
type of agonist used, AHR-driven signals could exert differential
modulation of Th responses and act as initiators or attenuators of
tissue- damage T cell-dependent inflammatory processes.
Through the AHR expression MPA, may potentially decrease
immune function by decreasing T cell IFN-γ and IL-17A
production, thereby influencing certain aspects of infection
progression. By increasing IL-22 and decreasing IL-17A,
MPA may be tissue protective (83). IL-22 induced by MPA
could act as a protective hormone thereby counteracting the
destructive effects of the immunoresponse. MPA may also limit
the tissue damage observed in some autoimmune disorders,
and may attenuate the inflammatory processes (81) in some
autoimmune disorders.
The biology and pharmacology of progestins and their
receptors are complex. Our understanding of their action
in certain physiologic targets including the immune system
continues to grow. The specific effects of hormones, including
synthetic progestins, depend upon their preparation, dose,
sequence of administration and context of treatment. The
observation that ubquitously used doses of MPA influence the
immune response of women adds yet another level of complexity
to the design and prescription of hormone therapy, whether it
be contraception or HRT, particularly in women with coexisting
immune disorders and infections.
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